WO1999000134A1 - New combination of antiasthma medicaments - Google Patents

New combination of antiasthma medicaments Download PDF

Info

Publication number
WO1999000134A1
WO1999000134A1 PCT/SE1998/001089 SE9801089W WO9900134A1 WO 1999000134 A1 WO1999000134 A1 WO 1999000134A1 SE 9801089 W SE9801089 W SE 9801089W WO 9900134 A1 WO9900134 A1 WO 9900134A1
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
rofleponide
composition
solvate
patient
Prior art date
Application number
PCT/SE1998/001089
Other languages
French (fr)
Inventor
Bengt Axelsson
Leif Källström
Jan Trofast
Original Assignee
Astra Aktiebolag (Publ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU81350/98A priority Critical patent/AU8135098A/en
Priority to SK1847-99A priority patent/SK184799A3/en
Priority to EEP199900594A priority patent/EE9900594A/en
Priority to BR9810452-7A priority patent/BR9810452A/en
Priority to IL13359798A priority patent/IL133597A0/en
Priority to CA002295076A priority patent/CA2295076A1/en
Application filed by Astra Aktiebolag (Publ) filed Critical Astra Aktiebolag (Publ)
Priority to PL98337722A priority patent/PL337722A1/en
Priority to JP50547999A priority patent/JP2002510310A/en
Priority to EP98931163A priority patent/EP1009408A1/en
Publication of WO1999000134A1 publication Critical patent/WO1999000134A1/en
Priority to IS5303A priority patent/IS5303A/en
Priority to NO996438A priority patent/NO996438L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Definitions

  • the present invention relates to compositions and methods useful in the treatment of respiratory disorders, particularly asthma.
  • asthma Despite recent advances in the awareness of asthma and the introduction of powerful and effective anti-asthma drugs, asthma remains a poorly understood and frequently poorly treated disease. There have been recent advances in the treatment of the disease which result from the recognition that asthma is a chronic inflammatory disease. Therapy is now aimed at both controlling the symptoms and reducing the inflammation. The symptoms include uncontrolled airway inflammation which may lead to mucosal damage and structural changes possibly leading to irreversible narrowing of the airways and fibrosis of the lungs.
  • the symptoms may be controlled by ⁇ 2 -adrenoreceptor agonists such as salbutamol, bambuterol, clenbuterol, fenoterol, procaterol, bitolterol, broxaterol, salmeterol, terbutaline and formoterol.
  • ⁇ 2 -adrenoreceptor agonists such as salbutamol, bambuterol, clenbuterol, fenoterol, procaterol, bitolterol, broxaterol, salmeterol, terbutaline and formoterol.
  • Prophylactic therapy is typically provided by steroids such as beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, dexamethasone, tipredane, ciclesonid, momethasone, RPR 106541, fluticasone or fluticasone propionate and budesonide or by way of sodium cromoglycate or nedocromil sodium.
  • steroids such as beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, dexamethasone, tipredane, ciclesonid, momethasone, RPR 106541, fluticasone or fluticasone propionate and budesonide or by way of sodium cromoglycate or nedocromil sodium.
  • the invention is based on the discovery that formeterol and rofleponide esters, or their salts or solvates, when administered to a patient either concurrently or sequentially, are unexpectedly effective in treating respiratory disorders involving inflammation, such as asthma.
  • the invention features a composition having, in an admixture: (a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt; and (b) a second active ingredient which is rofleponide or a fatty acid ester of rofleponide.
  • the molar ratio of (a) to (b) is from 1:1 to 1 :100, preferably from 1 : 1 to 1 :60, more preferably from 1 : 1 to 1 :35, and most preferably from 1 :16.
  • the first active ingredient (a) of the composition can be, for example, formoterol fumarate dihydrate, and the second active ingredient (b) of the composition can be, for example, rofleponide palmitate.
  • the composition can be provided in the form of a dry powder, the particles of which may have a mass median diameter of less than lO ⁇ m.
  • the invention also includes a kit containing: (a) a vessel containing a first active ingredient that is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt; (b) a vessel containing a second active ingredient that is either rofleponide or a fatty acid ester of rofleponide; and (c) instructions for the sequential or simultaneous admimstration of the first and second active ingredients to a patient in need thereof.
  • a patient suffering from a respiratory disorder such as asthma can be treated by administering (e.g., via inhalation), simultaneously or sequentially, (a) a dose of a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate thereof, and a solvate of such a salt; and (b) a dose of a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide.
  • the active ingredients can be provided to the patient for inhalation in dry powder form.
  • the active ingredients can be administered in either order, and within a two-hour time period.
  • the first active ingredient can be administered to the patient less than about 30 minutes after the second active ingredient, or the second active ingredient can be administered to the patient less than about 30 minutes after the first active ingredient.
  • the combination according to the invention has the advantage that the toal dose of each active ingredient can be decreased and is more likely to provide patient compliance then would be extected from the properties of the individual active ingredients.
  • the invention provides a composition having (a) a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate of formoterol, and a solvate of such a salt; (b) a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide; and, optionally, (c) one or more pharmaceutically acceptable additives, diluents or carriers.
  • the first and second active ingredients of the composition can be administered simultaneously or sequentially to treat respiratory disorders.
  • simultaneous is meant that the first and second active ingredients (a) and (b) are administered concomitantly, for example as an admixture.
  • Sequential administration generally comprises administering one immediately after the other. They still have the desired effect if they are administered separately but not more than about two hours apart, for example no more than 30 minutes and preferably no more than 5 minutes apart.
  • the composition is administered to provide a daily dose of from 0.5 to 200 nmol (preferably from 4 to 100 nmol) of (a) and from 0.5 to 1140 nmol (preferably 14 to 285 nmol and more preferably from 14 to 285 nmol) of (b) (subject to the molar ratio of (a) to (b) being from 1 :1 to 1 :100).
  • the preferred daily dose is from 0.2 to 84 ⁇ g (preferably from 2 to 42 ⁇ g) of (a), and from 0.4 to 800 ⁇ g (preferably from 10 to 400 ⁇ g, more preferably from 10 to 200 ⁇ g) of (b) where (b) is rofleponide pa nitate (subject to the molar ratio of (a) to (b) being within the range of from 1 : 1 to 1 : 100).
  • Suitable physiologically acceptable salts of formoterol include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4- hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene- carboxylate or oleate salts or solvates thereof.
  • Active ingredient (a) is preferably formoterol fumarate, especially as the dihydrate.
  • Rofleponide is preferably esterified by a palmitoyl group.
  • each of the active ingredients comprises one or more pharmaceutically acceptable additives, diluents or carriers, more preferably in an amount of from 50 to 2000 ⁇ g in a daily dose, most preferably in an amount of from 100 to 1000 ⁇ g.
  • suitable diluents or carriers include lactose, dextran, mannitol and glucose.
  • lactose is used.
  • active ingredient (b) is preferably a fatty acid ester
  • formulations containing it are desirably liposomal or proliposomal if they are dry powder formulations.
  • Suitable proliposomal formulations of fatty acid esters of rofleponide are described in WO
  • the formulation may comprise tocopherol, especially ⁇ - tocopherol.
  • Active ingredients (a) and (b) may optionally be formulated together to be administered simultaneously.
  • they may be formulated in admixture as a proliposomal powder, for example of the general type described in WO 96/19199
  • One or more of the active ingredients according to the invention are preferably in the form of a dry powder, more preferably a micronised dry powder, e.g. having a mass median diameter of less than lO ⁇ m, for example from 1 to 5 ⁇ m, most preferably an agglomerated micronised dry powder.
  • active ingredient (a) may be in the form of an ordered mixture with ingredient (c).
  • the ingredients used in the invention can be obtained in these preferred forms using methods known to those of skill in the art.
  • the invention further provides a method of treating a respiratory disorder, which is preferably asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis, which method comprises applying to a patient suffering from, or liable to suffer from, such a disorder a therapeutically effective amount of a combination according to the invention.
  • a respiratory disorder which is preferably asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis
  • COPD chronic obstructive pulmonary disease
  • rhinitis which method comprises applying to a patient suffering from, or liable to suffer from, such a disorder a therapeutically effective amount of a combination according to the invention.
  • an admixture or kit according to the invention in the manufacture of a medicament for simultaneous, separate or sequential use in therapy, preferably in the treatment of a respiratory disorder, e.g. asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis.
  • a respiratory disorder e.g. asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis.
  • COPD chronic obstructive pulmonary disease
  • Administration may be by inhalation orally or intranasally.
  • the ingredients are preferably adapted to be administered from a dry powder inhaler.
  • the combination may optionally be administered as divided doses from 1 to 4, and preferably once or twice a day, which means unit doses from 0.05 ⁇ g to 84 ⁇ g (preferably from 0.5 ⁇ g to 42 ⁇ g) of formoterol fumarate dihydrate and from 0.1 ⁇ g to 800 ⁇ g (preferably from 2.5 ⁇ g to 400 ⁇ g) of rofleponide pahnitate.
  • Example 1 Rofleponide pahnitate (10 parts by weight), dipalmitoylphosphatidylcholine (63 parts), dimyristoylphosphatidylcholine (24 parts), sodium dipalmitoylphosphatidylglycerol (3 parts) and racemic ⁇ -tocopherol (0.1 part) were dissolved in tertiary butanol (1300 parts) at 80°C. The solution was poured onto the shelves of a freeze-dryer cooled to -35°C. The solution had reached this temperature after about 30 minutes, the pressure in the freeze- dryer was then reduced in order to induce sublimation of the solvent.

Abstract

The invention provides a composition or kit having as a first active ingredient formoterol, or a salt or solvate derivative thereof, and having as a second active ingredient ropfleponide, or a fatty acid ester thereof. Also disclosed are methods for treating respiratory disorders using this composition or kit.

Description

NEW COMBINATION OF ANTIASTHMA MEDICAMENTS
Field of the Invention
The present invention relates to compositions and methods useful in the treatment of respiratory disorders, particularly asthma.
Background of the Invention
Despite recent advances in the awareness of asthma and the introduction of powerful and effective anti-asthma drugs, asthma remains a poorly understood and frequently poorly treated disease. There have been recent advances in the treatment of the disease which result from the recognition that asthma is a chronic inflammatory disease. Therapy is now aimed at both controlling the symptoms and reducing the inflammation. The symptoms include uncontrolled airway inflammation which may lead to mucosal damage and structural changes possibly leading to irreversible narrowing of the airways and fibrosis of the lungs.
The symptoms may be controlled by β2-adrenoreceptor agonists such as salbutamol, bambuterol, clenbuterol, fenoterol, procaterol, bitolterol, broxaterol, salmeterol, terbutaline and formoterol.
Prophylactic therapy is typically provided by steroids such as beclomethasone dipropionate (BDP), beclomethasone monopropionate (BMP), flunisolide, triamcinolone acetonide, dexamethasone, tipredane, ciclesonid, momethasone, RPR 106541, fluticasone or fluticasone propionate and budesonide or by way of sodium cromoglycate or nedocromil sodium. Summary of the Invention
The invention is based on the discovery that formeterol and rofleponide esters, or their salts or solvates, when administered to a patient either concurrently or sequentially, are unexpectedly effective in treating respiratory disorders involving inflammation, such as asthma. Accordingly, the invention features a composition having, in an admixture: (a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt; and (b) a second active ingredient which is rofleponide or a fatty acid ester of rofleponide.
It is preferred that the molar ratio of (a) to (b) is from 1:1 to 1 :100, preferably from 1 : 1 to 1 :60, more preferably from 1 : 1 to 1 :35, and most preferably from 1 :16.
The first active ingredient (a) of the composition can be, for example, formoterol fumarate dihydrate, and the second active ingredient (b) of the composition can be, for example, rofleponide palmitate.
The composition can be provided in the form of a dry powder, the particles of which may have a mass median diameter of less than lOμm.
The invention also includes a kit containing: (a) a vessel containing a first active ingredient that is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt; (b) a vessel containing a second active ingredient that is either rofleponide or a fatty acid ester of rofleponide; and (c) instructions for the sequential or simultaneous admimstration of the first and second active ingredients to a patient in need thereof.
A patient suffering from a respiratory disorder such as asthma can be treated by administering (e.g., via inhalation), simultaneously or sequentially, (a) a dose of a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate thereof, and a solvate of such a salt; and (b) a dose of a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide. The active ingredients can be provided to the patient for inhalation in dry powder form.
When administered sequentially, the active ingredients can be administered in either order, and within a two-hour time period. For example, the first active ingredient can be administered to the patient less than about 30 minutes after the second active ingredient, or the second active ingredient can be administered to the patient less than about 30 minutes after the first active ingredient.
Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.
The combination according to the invention has the advantage that the toal dose of each active ingredient can be decreased and is more likely to provide patient compliance then would be extected from the properties of the individual active ingredients.
Detailed Description
The invention provides a composition having (a) a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate of formoterol, and a solvate of such a salt; (b) a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide; and, optionally, (c) one or more pharmaceutically acceptable additives, diluents or carriers.
It has been found, using a sephadex-induced edema model (Kallstrόm et al., Agents and Action 17:355-377 (1985)), that the combination of active ingredients provides a significantly enhanced anti-inflammatory effect compared to the sum of the individual anti- inflammatory effects of the two active ingredients, thus providing a significant advantage. The first and second active ingredients of the composition can be administered simultaneously or sequentially to treat respiratory disorders. By simultaneous is meant that the first and second active ingredients (a) and (b) are administered concomitantly, for example as an admixture. Sequential administration generally comprises administering one immediately after the other. They still have the desired effect if they are administered separately but not more than about two hours apart, for example no more than 30 minutes and preferably no more than 5 minutes apart.
Preferably the composition is administered to provide a daily dose of from 0.5 to 200 nmol (preferably from 4 to 100 nmol) of (a) and from 0.5 to 1140 nmol (preferably 14 to 285 nmol and more preferably from 14 to 285 nmol) of (b) (subject to the molar ratio of (a) to (b) being from 1 :1 to 1 :100). When (a) is formoterol fumarate dihydrate, the preferred daily dose is from 0.2 to 84 μg (preferably from 2 to 42 μg) of (a), and from 0.4 to 800 μg (preferably from 10 to 400 μg, more preferably from 10 to 200 μg) of (b) where (b) is rofleponide pa nitate (subject to the molar ratio of (a) to (b) being within the range of from 1 : 1 to 1 : 100). Suitable physiologically acceptable salts of formoterol include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulphate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4- hydroxybenzoate, 4-chlorobenzoate, p-toluenesulphonate, methanesulphonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene- carboxylate or oleate salts or solvates thereof. Active ingredient (a) is preferably formoterol fumarate, especially as the dihydrate.
Rofleponide is preferably esterified by a palmitoyl group.
Preferably each of the active ingredients comprises one or more pharmaceutically acceptable additives, diluents or carriers, more preferably in an amount of from 50 to 2000 μg in a daily dose, most preferably in an amount of from 100 to 1000 μg. Examples of suitable diluents or carriers include lactose, dextran, mannitol and glucose. Preferably lactose is used.
Since active ingredient (b) is preferably a fatty acid ester, formulations containing it are desirably liposomal or proliposomal if they are dry powder formulations. Suitable proliposomal formulations of fatty acid esters of rofleponide are described in WO
96/19199. For improved stability the formulation may comprise tocopherol, especially α- tocopherol.
Active ingredients (a) and (b) may optionally be formulated together to be administered simultaneously. For example, they may be formulated in admixture as a proliposomal powder, for example of the general type described in WO 96/19199
(preferably containing tocopherol as a stabilizing agent) or as an intimate mixture of (a) in the form of a dry powder and a proliposomal dry powder containing (b).
One or more of the active ingredients according to the invention are preferably in the form of a dry powder, more preferably a micronised dry powder, e.g. having a mass median diameter of less than lOμm, for example from 1 to 5μm, most preferably an agglomerated micronised dry powder. Alternatively active ingredient (a) may be in the form of an ordered mixture with ingredient (c). The ingredients used in the invention can be obtained in these preferred forms using methods known to those of skill in the art.
The invention further provides a method of treating a respiratory disorder, which is preferably asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis, which method comprises applying to a patient suffering from, or liable to suffer from, such a disorder a therapeutically effective amount of a combination according to the invention.
According to the invention there is further provided the use of an admixture or kit according to the invention in the manufacture of a medicament for simultaneous, separate or sequential use in therapy, preferably in the treatment of a respiratory disorder, e.g. asthma, chronic obstructive pulmonary disease (COPD) and/or rhinitis.
Administration may be by inhalation orally or intranasally. The ingredients are preferably adapted to be administered from a dry powder inhaler.
The combination may optionally be administered as divided doses from 1 to 4, and preferably once or twice a day, which means unit doses from 0.05 μg to 84 μg (preferably from 0.5 μg to 42 μg) of formoterol fumarate dihydrate and from 0.1 μg to 800 μg (preferably from 2.5 μg to 400 μg) of rofleponide pahnitate.
Example 1 Rofleponide pahnitate (10 parts by weight), dipalmitoylphosphatidylcholine (63 parts), dimyristoylphosphatidylcholine (24 parts), sodium dipalmitoylphosphatidylglycerol (3 parts) and racemic α-tocopherol (0.1 part) were dissolved in tertiary butanol (1300 parts) at 80°C. The solution was poured onto the shelves of a freeze-dryer cooled to -35°C. The solution had reached this temperature after about 30 minutes, the pressure in the freeze- dryer was then reduced in order to induce sublimation of the solvent. While the rate of sublimation could be adjusted by decreasing the pressure and increasing the temperature, the temperature throughtout the process was not allowed to exceed -10°C. Freeze-drying was continued until all the solvent had been removed. The resulting powder was scraped from the shelves of the freeze-dryer and passed through a sieve. This powder was micronised in an air jet mill to a powder particle size of less than 5 μm. 0.5 parts of formoterol fumarate dihydrate was mixed with 79.5 parts of lactose monohydrate. The blend was micronised using a high pressure air jet mill and then conditioned using the process of EP-A-717 616. This mixture (80 parts) was added to the steroid/lipid powder mixture (20 parts) by mixing and homogenising with a low pressure jet mill. The mixture was then spheronised using the process of EP-A-721 331 and filled into a blister, a capsule or a storage chamber of an inhaler for use in a dry powder inhaler.
Other Embodiments
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

What is claimed is:
1. A therapeutic composition comprising, in admixture:
(a) a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate thereof, and a solvate of such a salt; and
(b) a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide.
2. The composition of claim 1, wherein the molar ratio of (a) to (b) in the composition is
Figure imgf000009_0001
3. The composition of claim 1 or 2, wherein (a) is formoterol fumarate dihydrate.
4. The composition of any one of claims 1 to 3, wherein (b) is rofleponide pahnitate.
5. The composition of any one of claims 1 to 4, additionally comprising a pharmaceutically acceptable additive, diluent or carrier suitable for inhalation.
6. The composition of any one of claims 1 to 5, in the form of a dry powder the particles of which have a mass median diameter of less than 1 O╬╝m.
7. A kit comprising
(a) a vessel containing a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate thereof, and a solvate of such a salt;
(b) a vessel containing a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide; and
(c) instructions for the sequential or simultaneous admimstration of the first and second active ingredients to a patient in need thereof.
8. The kit of claim 7, wherein the first active ingredient is formoterol fumarate dihydrate.
9. The kit of claim 7 or 8, wherein the second active ingredient is rofleponide palmitate.
10. The kit of any one of claims 7 to 9, wherein the instructions specify that the first and second active ingredients be administered in a molar ratio ranging from 1 : 1 to 1 : 100.
11. A method of treating a respiratory disorder, which method comprises simultaneously or sequentially administering to a patient suffering from the disorder (a) a dose of a first active ingredient selected from the group consisting of formoterol, a pharmaceutically acceptable salt or solvate thereof, and a solvate of such a salt; and
(b) a dose of a second active ingredient selected from the group consisting of rofleponide and a fatty acid ester of rofleponide.
12. The method of claim 11, wherein the molar ratio of (a) to (b) is from 1:1 to 1:100.
13. The method of claim 11 or 12, wherein the first active ingredient is formoterol fumarate dihydrate.
14. The method of any one of claims 11 to 13, wherein the second active ingredient is rofleponide palmitate.
15. The method of any one of claims 11 to 14, wherein the first active ingredient is administered to the patient less than about 30 minutes before and after the second active ingredient.
16. The method of any one of claims 11 to 15, wherein the doses are administered to the patient by causing the patient to inhale them simultaneously.
17. The method of claim 16, wherein the first and second active ingredients are both provided to the patient for inhalation in dry powder form.
PCT/SE1998/001089 1997-06-27 1998-06-08 New combination of antiasthma medicaments WO1999000134A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SK1847-99A SK184799A3 (en) 1997-06-27 1998-06-08 New combination of antiasthma medicaments
EEP199900594A EE9900594A (en) 1997-06-27 1998-06-08 New anti-asthma formulations
BR9810452-7A BR9810452A (en) 1997-06-27 1998-06-08 New combination of asthma drugs
IL13359798A IL133597A0 (en) 1997-06-27 1998-06-08 New combination of antiasthma medicaments
CA002295076A CA2295076A1 (en) 1997-06-27 1998-06-08 New combination of antiasthma medicaments
AU81350/98A AU8135098A (en) 1997-06-27 1998-06-08 New combination of antiasthma medicaments
PL98337722A PL337722A1 (en) 1997-06-27 1998-06-08 Novel combination antiasthmatic drugs
JP50547999A JP2002510310A (en) 1997-06-27 1998-06-08 New combination of anti-asthma drugs
EP98931163A EP1009408A1 (en) 1997-06-27 1998-06-08 New combination of antiasthma medicaments
IS5303A IS5303A (en) 1997-06-27 1999-12-15 A new combination of asthma
NO996438A NO996438L (en) 1997-06-27 1999-12-23 New combination of anti-asthma drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88382397A 1997-06-27 1997-06-27
US08/883,823 1997-06-27

Publications (1)

Publication Number Publication Date
WO1999000134A1 true WO1999000134A1 (en) 1999-01-07

Family

ID=25383399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1998/001089 WO1999000134A1 (en) 1997-06-27 1998-06-08 New combination of antiasthma medicaments

Country Status (16)

Country Link
EP (1) EP1009408A1 (en)
JP (1) JP2002510310A (en)
KR (1) KR20010014162A (en)
AU (1) AU8135098A (en)
BR (1) BR9810452A (en)
CA (1) CA2295076A1 (en)
EE (1) EE9900594A (en)
HU (1) HUP0002533A3 (en)
ID (1) ID24063A (en)
IL (1) IL133597A0 (en)
IS (1) IS5303A (en)
NO (1) NO996438L (en)
PL (1) PL337722A1 (en)
SK (1) SK184799A3 (en)
TR (1) TR199903272T2 (en)
WO (1) WO1999000134A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053187A1 (en) * 1999-03-09 2000-09-14 Astrazeneca Ab New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
WO2001078746A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Respiratory compositions
WO2001078738A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical compositions comprising (r,r)-formoterol and rofleponide
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US6824761B1 (en) 1999-05-28 2004-11-30 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
US7348362B2 (en) 2003-07-10 2008-03-25 Dey, L.P. Bronchodilating β-agonist compositions and methods
US7897646B2 (en) 1997-09-19 2011-03-01 Astrazeneca Ab Use for budesonide and formoterol
US8623851B2 (en) 2001-04-17 2014-01-07 Mylan Specialty L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US9295644B2 (en) 1998-06-11 2016-03-29 Astrazeneca Ab Methods and compositions for treating asthma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
WO1995005805A1 (en) * 1993-08-27 1995-03-02 Astra Aktiebolag Process for conditioning substances
WO1996019199A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Proliposome powders for inhalation
WO1996032095A1 (en) * 1995-04-13 1996-10-17 Astra Aktiebolag Process for the preparation of respirable particles
WO1998015280A1 (en) * 1996-10-08 1998-04-16 Astra Aktiebolag New combination

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
WO1995005805A1 (en) * 1993-08-27 1995-03-02 Astra Aktiebolag Process for conditioning substances
WO1996019199A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Proliposome powders for inhalation
WO1996032095A1 (en) * 1995-04-13 1996-10-17 Astra Aktiebolag Process for the preparation of respirable particles
WO1998015280A1 (en) * 1996-10-08 1998-04-16 Astra Aktiebolag New combination

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897646B2 (en) 1997-09-19 2011-03-01 Astrazeneca Ab Use for budesonide and formoterol
US8461211B2 (en) 1997-09-19 2013-06-11 Astrazeneca Ab Use for budesonide and formoterol
US9295644B2 (en) 1998-06-11 2016-03-29 Astrazeneca Ab Methods and compositions for treating asthma
US7273604B2 (en) 1998-11-26 2007-09-25 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
WO2000053187A1 (en) * 1999-03-09 2000-09-14 Astrazeneca Ab New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
US6824761B1 (en) 1999-05-28 2004-11-30 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
WO2001078746A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Respiratory compositions
WO2001078738A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical compositions comprising (r,r)-formoterol and rofleponide
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US9597396B2 (en) 2001-04-17 2017-03-21 Mylan Specialty Lp Formoterol/steroid bronchodilating compositions and methods of use thereof
US8623851B2 (en) 2001-04-17 2014-01-07 Mylan Specialty L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US7541385B2 (en) 2003-07-10 2009-06-02 Chaudry Imtiaz A Bronchodilating β-agonist compositions and methods
US7473710B2 (en) 2003-07-10 2009-01-06 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7465756B2 (en) 2003-07-10 2008-12-16 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7462645B2 (en) 2003-07-10 2008-12-09 Jpmorgan Chase Bank, N.A. Bronchodilating beta-agonist compositions and methods
US7348362B2 (en) 2003-07-10 2008-03-25 Dey, L.P. Bronchodilating β-agonist compositions and methods
US9730890B2 (en) 2003-07-10 2017-08-15 Mylan Pharmaceuticals, Inc. Bronchodilating beta-agonist compositions and methods

Also Published As

Publication number Publication date
KR20010014162A (en) 2001-02-26
IS5303A (en) 1999-12-15
AU8135098A (en) 1999-01-19
EP1009408A1 (en) 2000-06-21
BR9810452A (en) 2000-09-05
JP2002510310A (en) 2002-04-02
CA2295076A1 (en) 1999-01-07
TR199903272T2 (en) 2000-08-21
NO996438D0 (en) 1999-12-23
IL133597A0 (en) 2001-04-30
HUP0002533A3 (en) 2001-03-28
HUP0002533A2 (en) 2000-12-28
EE9900594A (en) 2000-08-15
SK184799A3 (en) 2000-06-12
ID24063A (en) 2000-07-06
NO996438L (en) 2000-02-28
PL337722A1 (en) 2000-08-28

Similar Documents

Publication Publication Date Title
AU715319B2 (en) New combination
EP1085877B1 (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
AU673660C (en) New combination of formoterol and budesonide
US7897646B2 (en) Use for budesonide and formoterol
WO2000053187A1 (en) New combination of formoterol and mometasone in a pharmaceutical composition for treating respiratory disorders, such as asthma, rhinitis and copd
EP1009408A1 (en) New combination of antiasthma medicaments
WO2000053188A1 (en) New combination of r,r-formoterol and budesonide in a pharmaceutical composition useful for treating respiratory disorders, such as asthma, rhinitis and copd
EP1101493A2 (en) New combination of formoterol and budesonide
MXPA99011676A (en) New combination of antiasthma medicaments
CZ466899A3 (en) Novel combination of anti-asthmatic medicaments
MXPA98004357A (en) New combination
MXPA00011806A (en) Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 133597

Country of ref document: IL

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 81350/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998931163

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 98805891.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 501673

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/011676

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV1999-4668

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2295076

Country of ref document: CA

Ref document number: 2295076

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 184799

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1019997012233

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999/03272

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: PV1999-4668

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998931163

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997012233

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-4668

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1998931163

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997012233

Country of ref document: KR